In India, Finecure is built on an ethical, prescription-led branded portfolio - brands that physicians recognise and prescribe, and that patients ask for by name. Trusted by more than 40,000 prescribing practitioners and stocked across over 80,000 retail pharmacies through a pan-India network, the branded Rx business offers distribution and trade partners a portfolio that already carries demand. For government and hospital procurement, Finecure’s five state-of-the-art manufacturing blocks provide the volume assurance and ISO-governed quality that institutional and tender supply require.
Finecure's branded prescription business reaches 40,000+ prescribing practitioners and is stocked at 80,000+ pharmacies across India, across seven therapeutic verticals. The Neocardiabcare division carries the cardiovascular and metabolic range; brand families include FINEMOX and FINETRIAX in anti-infectives, BPGARD and CAROSU in cardiovascular, RABIFINE and PEPCARE in gastrointestinal, and MYNERVE in neurology.
Naming the brand families does two things. It gives a domestic distributor something recognisable to respond to, and it gives an export buyer evidence that these are commercialised products with a market history rather than a paper catalogue.
A deep pan-India retail network stocking Finecure brands - strong reach and dependable reorder velocity.
Prescribing doctors who recommend our ethical branded formulations across Chronic, Acute, and OTC segments.
A distribution backbone built for continuous availability, plus institutional and tender fulfilment from five dedicated blocks.